156 related articles for article (PubMed ID: 34059328)
21. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
Vergnenegre A; Massuti B; de Marinis F; Carcereny E; Felip E; Do P; Sanchez JM; Paz-Arez L; Chouaid C; Rosell R;
J Thorac Oncol; 2016 Jun; 11(6):801-7. PubMed ID: 26899757
[TBL] [Abstract][Full Text] [Related]
22. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
23. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.
Qin S; Yi L; Li S; Tan C; Zeng X; Wang L; Peng Y; Wan X
Adv Ther; 2021 Jun; 38(6):3399-3408. PubMed ID: 34019245
[TBL] [Abstract][Full Text] [Related]
25. Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review.
Gharaibeh M; Bootman JL; McBride A; Martin J; Abraham I
Pharmacoeconomics; 2017 Jan; 35(1):83-95. PubMed ID: 27637757
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial.
Huang J; Liao W; Zhou J; Zhang P; Wen F; Wang X; Zhang M; Zhou K; Wu Q; Li Q
Cancer Manag Res; 2018; 10():4065-4072. PubMed ID: 30323662
[TBL] [Abstract][Full Text] [Related]
27. Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer.
Ko AH
J Clin Oncol; 2023 Oct; 41(30):4711-4712. PubMed ID: 37847994
[No Abstract] [Full Text] [Related]
28. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.
Zhu J; He W; Ye M; Fu J; Chu YB; Zhao YY; Zhang YJ; Kuo D; Wu B
Future Oncol; 2018 Nov; 14(27):2833-2840. PubMed ID: 29878848
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument.
Jayakrishnan TT; Nadeem H; Groeschl RT; George B; Thomas JP; Ritch PS; Christians KK; Tsai S; Evans DB; Pappas SG; Gamblin TC; Turaga KK
HPB (Oxford); 2015 Feb; 17(2):131-9. PubMed ID: 25123702
[TBL] [Abstract][Full Text] [Related]
31. Role of erlotinib in the management of pancreatic cancer.
Starling N; Neoptolemos J; Cunningham D
Ther Clin Risk Manag; 2006 Dec; 2(4):435-45. PubMed ID: 18360654
[TBL] [Abstract][Full Text] [Related]
32. Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities.
Choi BM; Abraham RB; Halawah H; Calamia M; Obeng-Kusi M; Alrawashdh N; Arku D; Abraham I
J Med Econ; 2021 Nov; 24(sup1):34-41. PubMed ID: 34866529
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy with gemcitabine plus erlotinib
Wisniewski M; Placide PA; Granier S; Al Shatti Y; Al Qalaf S; Bouattour M; Lamuraglia M; Hammel P
Hepatobiliary Surg Nutr; 2018 Oct; 7(5):399-402. PubMed ID: 30498718
[No Abstract] [Full Text] [Related]
34. Cost-Effectiveness Analysis and Volume-Based Surgical Care.
Perry LM; Bold RJ; Hoch JS
J Am Coll Surg; 2022 Feb; 234(2):249-250. PubMed ID: 35213449
[No Abstract] [Full Text] [Related]
35. Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy.
Cai H; Wang R; Guo X; Song M; Yan F; Ji B; Liu Y
Mol Pharm; 2021 Jul; 18(7):2495-2506. PubMed ID: 34078087
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis.
Lin S; Liu T; Chen J; Li G; Dang J
PLoS One; 2021; 16(6):e0252751. PubMed ID: 34086780
[TBL] [Abstract][Full Text] [Related]
37. Successful retreatment with erlotinib after erlotinib-related interstitial lung disease.
Turk HM; Adli M; Simsek M; Aliyev A; Besiroglu M
Tumori; 2021 Dec; 107(6):NP84-NP86. PubMed ID: 34082639
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial resistance in Neisseria gonorrhoeae isolates and gonorrhoea treatment in the Republic of Belarus, Eastern Europe, 2009-2019.
Aniskevich A; Shimanskaya I; Boiko I; Golubovskaya T; Golparian D; Stanislavova I; Jacobsson S; Adaskevich A; Unemo M
BMC Infect Dis; 2021 Jun; 21(1):520. PubMed ID: 34078300
[TBL] [Abstract][Full Text] [Related]
39. Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.
Duggirala KB; Lee Y; Lee K
Biomol Ther (Seoul); 2022 Jan; 30(1):19-27. PubMed ID: 34074804
[TBL] [Abstract][Full Text] [Related]
40. Re-use of erlotinib in a patient using osimertinib after erlotinib, case report.
Gursoy P
J Oncol Pharm Pract; 2022 Jan; 28(1):211-214. PubMed ID: 34074173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
